INTRODUCTION
In 1975, LaBrecque and Pesch first found the existence of HSS (hepatic stimulator substance) in the liver cytosol of weanling or adult partially hepatectomized rats [1] . Initially, HSS was demonstrated to promote hepatocyte proliferation and regeneration after liver injury. Later, several in vitro studies demonstrated that although HSS stimulates hepatic growth in dividing hepatocytes it is unable to promote an independently resting-state adult liver [2] . Instead, it augmented the mitogenic effects of other growth factors, such as EGF (epidermal growth factor). This property of the protein has prompted researchers in the field to rename HSS as ALR (augmenter of liver regeneration) [3] . More recent studies have found that ALR has amazingly diverse functions, for instance, it regulates flavine adenine dinucleotide-linked, oxidative phosphorylationgenerating disulfide bridges in proteins, biogenesis of cytosolic Fe/S proteins and electron transfer via FAD to cytochrome c [4] .
The ALR gene forms alternative-splicing products, resulting in two different protein forms: a shorter protein of 125 amino acids that exists only in the nucleus, and a longer protein of 205 amino acids that may be responsible for mitochondrial localization due to potential N-terminal signalling peptides [5] .
Because ALR is expressed in multiple tissues and has different subcellular localizations and diverse functions, it is believed that ALR participates not only in the regulation of liver regeneration and biogenesis of mitochondria, but also in mammalian liver development [6] . Owing to its potential roles in these pathways, some alterations in HSS gene expression have occurred in relation to pathological states such as acute liver disease, liver cirrhosis and carcinoma [7, 8] .
The hHSS (human HSS) gene has been isolated and mapped to chromosome 16 [9] . The hHSS promoter has also been studied. It was reported that the minimal promoter of hHSS is TATA-less and spans positions −54 to +42 relative to the transcriptional start point [10] , which is different from our recent findings in hepatic HepG2 cells and non-liver COS7 cells [11] . In that report, we showed that regulation of hHSS transcription by the AP (activator protein) 1/AP4 cis-acting element (−375/−369 nt) appeared with dual effects in different cell lines. c-Jun binds to the AP1/AP4 cisacting element and down-regulates the expression of the hHSS gene in HepG2 cells, whereas AP4 binds to the same region and up-regulates its expression in COS7 cells. The tissue-specific function of c-Jun with regard to hHSS promoter activity may in part help to explain the differences in the biological function of hHSS between liver and non-liver cells. However, regulation
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In the present study, we delineated the transcriptional regulation mechanism of the −252/−49 region from the transcriptional start site of the hHSS gene in human hepatocytes, which contains all of the elements for basal transcription. The aim of the present study was to define (i) what cis-acting elements are required for transcription of the hHSS gene, (ii) how these trans-acting factors are involved in this process, and (iii) which mechanism is responsible for regulation of hHSS gene transcription.
EXPERIMENTAL

Recombinant plasmids
For promoter deletion and site-mutagenesis assays, the hHSS promoter-luciferase chimaeric constructs were created by PCR amplification. The forward primer contained a SacI site, and the reverse primer contained a HindIII site (Table 1) . These restriction sites were used for cloning the hHSS promoter fragments into the luciferase reporter pGL3-basic (Promega). All deletions and site-directed mutants were confirmed by DNA sequencing. The resultant constructs that contained different lengths of the hHSS promoter were named as P49-luc, P92-luc, P132-luc, P145-luc, P152-luc, P172-luc, P192-luc and P212-luc. Similarly, a series of mutant plasmids were referred to as MSp1 P145-luc, MC/EBP P172-luc, MNF1 P172-luc, MHNF4 P212-luc and MSp1 P212-luc. The wild-type HNF4α (hepatocyte nuclear factor 4α) expression plasmid (designated HNF4exp) was a gift from Dr Mary C. Weiss (Departement de Biologie du Developpement of Institut Pasteur, Paris, France). Plasmids pCMV-HNF4α1 and pCMV-HNF4α7 were kindly provided by Dr M.-J. Vilarem (Montpellier University, Montpellier, France). The wild-type Sp1 (stimulating protein 1) expression vector, pPacSp1, and Sp1 frameshift mutant expression vector that did not express Sp1, pFXSp1, were kindly provided by Dr Andrew D. Yurochko (Lineberger Comprehensive Cancer Center, University of North Carolina, NC, U.S.A.) [12] .
Cell culture, transfection and luciferase assay
Human hepatoma cells (HepG2) were cultured in MEM (minimum essential medium; Hyclone) supplemented with 10 % (v/v) FBS (fetal bovine serum) under 5 % CO 2 at 37
• C. HNF4α-deficient HEK (human embryonic kidney)-293T cells were grown in DMEM (Dulbecco's modified Eagle's medium; Hyclone) supplemented with 5 % (v/v) FBS under 5 % CO 2 at 37
• C. Schneider's Drosophila Line 2 cells (SL-2) were cultured in Schneider's Drosophila Medium (Gibco) supplemented with 10 % (v/v) FBS at 23
• C. The cells were plated at a density of 4 × 10 4 cells/well on 96-well culture plates and transfected using Lipofectamine TM 2000 (Invitrogen) as described previously [11] . To perform cell transfection, 0.5 μg of the hHSS promoter construct and 0.02 μg of the Renilla luciferase expression vector pRL-TK (Promega), which was used as an internal control, were transfected into HepG2 cells. For co-transfection experiments, 0.5 μg of the HNF4α, HNF4α1, HNF4α7 or Sp1 expression plasmid was co-transfected with 0.5 μg of the hHSS promoter construct and 0.02 μg of pRL-TK. In addition, the expression vector pcDNA3.1 (Invitrogen) was used as an internal control to evaluate the effect of expression vectors on hHSS promoter activity. After transfection, the cells were assayed for both firefly and Renilla luciferase activities using a dual luciferase system (Promega) and a GloMax TM 96 microplate luminometer (Promega) according to the manufacturer's protocol. All promoter assay values were corrected for transfection efficiency by normalizing the firefly luciferase signal of the hHSS promoter constructs to the Renilla luciferase values derived from the control vector pRL-TK.
RNA extraction and real-time PCR
Total RNA extraction and real-time PCR were performed using methods previously described [13] . Reverse transcription was performed using the SuperScript TM III first-strand synthesis system (Invitrogen). Real-time PCR was then performed on the ABI Prism 7300 Sequence Detection System (Applied Biosystems) using the Power SYBR Green master kit to measure quantitatively the mRNA levels of hHSS, according to the manufacturer's protocol. A list of the primers used is shown in Table 1 . The β-actin gene was used as an internal control for all reactions.
EMSA (electrophoretic mobility-shift assay)
Nuclear protein extracts from HepG2 cells were prepared with NE-PER ® nuclear and cytoplasmic extraction reagents (Pierce). The EMSAs were performed using the LightShift ® chemiluminescent EMSA kit (Pierce) according to the manufacturer's protocol using nuclear protein extracts from HepG2 cells, human recombinant Sp1 (Promega) and Sp3 protein (Alexis). The 5 -biotin end-labelled oligonucleotides (Table 1) were synthesized in Shanghai Sangon Biological Engineering Technology and Services Company (Shanghai, China). In competition experiments, 4 pmol of non-labelled double-stranded oligonucleotide (Table 1 ) was added to the reaction mixture. In a supershift assay, 1 μg of anti-HNF4α antibody (Santa Cruz Biotechnology) or anti-Sp1 antibody (Santa Cruz Biotechnology) was incubated with nuclear extracts for 5 min at room temperature (25 • C) before the binding reaction. The biotin end-labelled DNA was detected using the streptavidin-horseradish peroxidase conjugate and LightShift ® chemiluminescent substrate (Pierce).
ChIP (chromatin immunoprecipitation) assay
The ChIP assay was performed according to the instructions of the ChIP assay kit (Upstate). For immunoprecipitation, anti-HNF4α or anti-Sp1 polyclonal antibodies were added. No addition of antibody and normal rabbit serum were used as negative controls. Nuclear DNA extracts were finally amplified using two-pair primers ( Table 1 ) that spanned the HNF4α and Sp1 sites (−255 to −27 bp and −192 to +98 bp) within the hHSS promoter respectively. For the transfected ChIP assay, HepG2 cells were transfected with 1.5 μg of either HNF4exp or pcDNA3.1. At 48 h after transfection, the cells were subjected to a ChIP assay using anti-HNF4α antibodies. The sequences of the primers are shown in Table 1 (−255 to −27 bp). For the transient ChIP assay, HepG2 cells were transfected with 1.5 μg of the wild-type promoter construct, P212-luc, and its mutants, MHNF4 P212-luc or MSp1 P212-luc, as described above. After 48 h incubation, the cells were analysed by ChIP assay as described above. The resulting DNA was analysed by PCR with a forward primer directed to the pGL3-basic (Promega) plasmid backbone (Table 1 ) and a reverse primer (HNF4 right, −46 to −27, Table 1 ) common to all constructs.
HNF4α RNA interference
The siRNA (small interfering RNA) sequence targeting human HNF4α cDNA (GenBank ® NM 00103003) has been described by Kamiyama et al. [14] and corresponds to nucleotides 640-658 [14] . Additionally, an siRNA construct that matched no known mammalian genes was selected for use as a negative control (GenePharma). The sequences of these siRNA are shown in Figure 6 
DEX (dexamethasone) treatment
HepG2 cells were cultured in a 60-mm dish at a density of 2 × 10 6 cells/dish. At 24 h in culture, the medium was replaced by fresh medium with 5 % charcoal-treated FBS (Biochrom), and the cells were treated with a final concentration of 0.001, 0.01, 0.1 and 1.0 μM DEX for 48 h. The cells were then harvested and applied to real-time PCR, ChIP, Western blot and EMSA assays to detect the effect of DEX on promoter activity. For the hHSS promoter-transfected cells (P212-luc or MHNF4 P212-luc), a final concentration of 0.001, 0.01, 0.1 and 1.0 μM DEX was also added and the luciferase assay was carried out 48 h later.
Decoy assay
Synthesis of double-stranded ODNs (oligodeoxynucleotides) and a decoy assay were carried out as previously described [15] . In brief, for transfection of ODNs, HepG2 cells were co-transfected with 0.5 μg of the hHSS reporter plasmid (P212-luc) and a final concentration of 0.15 μM ODN. After 18 h, the cells were treated with a final concentration of 0.1 μM DEX. At 48 h post-treatment, the cells were applied to the luciferase reporter-gene assay.
Western blot analysis
Western blot analysis was performed using methods previously described [13] . After treatment, 2 × 10 7 cells were harvested using a scraper and then nuclear and cytoplasmic protein extracts from HepG2 cells were prepared with NE-PER ® nuclear and cytoplasmic extraction reagents (Pierce). For electrophoresis, 50 μg of total cellular proteins or 70 μg of nuclear proteins were separated by SDS/PAGE (12 % gel) and electrotransfered on to a nitrocellulose membrane, and subsequently incubated with an anti-HNF4α polyclonal antibody (1:500). The proteins were visualized using ECL (enhanced chemiluminescence) reagents (Pierce). 
Data analysis
All values are expressed as means + − S.D. Statistical significance was determined using a t test. P values less than 0.05 were considered statistically significant.
RESULTS
Functional characterization of the hHSS proximal promoter
In our previous work, we have shown that the major regulatory elements of the hHSS gene promoter may exist in the region −252/−49 from the transcriptional start site, which takes into account nearly half of the promoter activity (> 50 %) [11] . To identify potential binding sites for transcription factors in the region that may be important in the regulation of hHSS gene expression, computer-assisted analysis using the TRANSFAC database [16] was performed. This region possessed the characteristics of a TATA-less promoter, namely, GC-rich sequences and multiple putative Sp1-binding sites. Also in this region several potential transcription-factor-binding sites including NF-1 (nuclear factor 1), C/EBP (CCAAT/enhancerbinding protein), AP2 and liver-enriched transcription factors, such as HNF4 (DR-1), were present, especially in the −212/−49 region ( Figure 1a ). Based upon the prediction, 212 bp in this region of the hHSS proximal promoter was cloned for the present study.
Five fragments with sizes ranging from −212 to −49 bp were generated by PCR using specific primers (Table 1) . These PCR products were all verified by DNA sequencing, inserted into a vector with a luciferase reporter gene (pGL3-basic) (Figure 1b ) and transiently transfected into human HepG2 hepatoma cells.
As shown in Figure 1(b) , the promoter activity of the P212 construct was approx. 11-fold higher than that of the parental promoter-less construct (pGL3 basic) in HepG2 cells. Deletion from −212 to −172 significantly increased the promoter activity approx. 4-5-fold, suggesting the presence of a strong inhibitory element in this region. In contrast, deletion to −132 resulted in an approx. 80 % decrease of the activity. Further deletions resulted in a slight reduction in luciferase activity. P172 displayed the maximum promoter activity, indicating that the regulatory elements present in the proximal regulatory region between −172 and −132 bp of the hHSS promoter are sufficient to recruit the basal transcriptional machinery. To explore the eligible cis-binding sites in the −172 to −132 region, we also generated additional deletions and site-directed mutations. As shown in Figure 2 , the deletion of a 7 bp fragment from −152 to −145 containing the putative Sp1 site (−152/−145) resulted in a substantial decrease (75 %) in the promoter activity. However, the promoter activity did not change with the deletion extended to −132 or mutation of the Sp1-binding site between −145 and −132, suggesting that the Sp1 site (−152/−145) was essential for the basal transcription of the hHSS gene. Mutations of the potential NF-1 and C/EBP sites within the region between −172 and −152 had no effect on the promoter activity. This suggested that NF-1 and C/EBP were not significantly involved in the promoter activity of hHSS in this reporter assay system. Therefore two cis-acting elements in the hHSS proximal promoter, the HNF4 site (−209/−204) and the Sp1 site (−152 to −145), might play dual functions in regulation of transcription.
Identification of transcription-factor-binding sites
Sp1 binds to the −152 to −145 region and drives hHSS promoter activity
To address whether Sp1 bound to the −152 to −145 region and underlies hHSS promoter activity, we first conducted a gel mobility-shift assay. Nuclear extracts from HepG2 cells were incubated with biotin-labelled P152132 probe ( Table 1) . As shown in Figure 3 (a), two specific bands of protein complexes were detected (lane 3), which were competed by a 200-fold molar excess of unlabelled P152132 probe and the consensus Sp1 oligos (lanes 1 and 2). Other competitors, the consensus binding sites for AP1 and AP2, were unable to compete away the complex formation (results not shown). Moreover, antibodies directed against human Sp1 supershifted nearly all of the complex (lane 4), whereas the normal rabbit serum had no effect (lane 8). A specific band of protein complexes was also detected (lane 9) when EMSA was performed using the human recombinant Sp1 protein, and it was competed by a 200-fold molar excess of unlabelled P152132 probe (lane 10). In addition, no specific band was detected when EMSA was performed using the human recombinant Sp3 protein (lane 11). These results clearly showed that Sp1 is able to bind the Sp1 site in the −152 to −145 region in vitro.
To further examine the role of Sp1 in regulating hHSS gene expression, we next transfected HepG2 cells with the wildtype Sp1 expression vector (pPacSp1) and the empty expression vector pcDNA3.1 as a negative control. After 48 h, RNA was extracted, and the abundance of hHSS mRNA was measured by real-time PCR. Overexpression of Sp1 increased the mRNA abundance approx. 1.5-fold (Figure 4a ) compared with the control transfection of pcDNA3.1, indicating that Sp1 can induce hHSS gene expression.
To further confirm the regulation of the hHSS gene by Sp1 via the Sp1-binding site in the −152 to −145 region, we observed the promoter activity in the HepG2 and Sp1-deficient SL-2 cells subjected to co-transfection of the promoter construct (P192) with either the Sp1-expression vector (pPacSp1), Sp1-mutant vector (pFXSp1) or pcDNA3.1 vector used as a mock transfection. As shown in Figure 4 (b), co-transfection of P192 with pPacSp1 induced luciferase gene expression by nearly 2.5-fold and 9-fold in the HepG2 and Sp1-deficient SL-2 cells respectively, compared with the luciferase activity in untransfected cells; whereas the mock transfection and negative control transfection (pFXSp1) brought about minor promoter inhibition. Co-transfection with an alternative construct in which the Sp1 site was deleted (−152/−145; Figure 1a) did not affect the luciferase activity (results not shown). These results suggested that the Sp1 site (−152/−145) plays an important role in regulating hHSS gene expression.
Finally, we performed ChIP assays with the hHSS promoter to test whether Sp1 was associated with the hHSS gene in vivo. results are consistent with the EMSA and supershift assays in Figure 3(a) .
Hence, these results strongly suggest that Sp1 is able to bind to the hHSS promoter under physiological conditions in vivo and is involved in regulation of hHSS basal expression by activating the basal promoter.
HNF4α binds to the −209 to −204 region and represses hHSS promoter activity
Another possible region responsible for the regulation of hHSS promoter activity, as determined by the promoter deletion and mutation experiments, was the region (−212/−192) traversing the HNF4-binding site (−209/−204), as shown in Figure 2 . Therefore we tested this DNA fragment in gel mobility-shift assays using HepG2 cell nuclear extract. As shown in Figure 3 (e) Transient ChIP assays of the wild-type hHSS promoter construct and its mutant derivatives. ChIP assays, including controls, were performed as described above. DNA was amplified using primers shown in Table 1 . The HNF4α-antibody-immunoprecipitated DNA fragments were detectable by PCR amplification from HepG2 cells transfected with P212-luc or MSp1P212-luc. No immunoprecipitated PCR product was detected when the HNF4α-binding cells. To do this, the HNF4α expression vector (HNF4exp) was transfected into cells and hHSS mRNA expression was measured after 48 h. Figure 5(a) shows that hHSS mRNA was dramatically reduced 4-fold when HNF4α was overexpressed. The influence of HNF4α on hHSS promoter activity was then investigated by co-transfection experiments in HepG2 and HNF4α-deficient HEK-293T cells. Figure 5(b) illustrates that the co-transfection of HNF4exp with the hHSS promoter-containing vector (P212-luc) dramatically inhibited the promoter activity to ∼ 30 % of control in both cell lines. However, co-transfection of the mutant HNF4α vector (MHNF4 P212-luc) with HNF4exp was unable to alter the promoter activity (Figure 5c ). These results suggested that binding of HNF4α to −209/−204 exerted a repressive effect on hHSS expression.
To determine whether the HNF4α transcription factor interacts with the hHSS promoter in vivo, ChIP analysis was employed using anti-HNF4α antibodies. Unexpectedly, a positive product could not be PCR-amplified from chromosomal DNA immunoprecipitated by anti-HNF4α antibodies (results not shown). In order to account for the negative result, we used ChIP to analyse transfected cells to identify whether HNF4α was capable of binding to the hHSS promoter in vivo. Expression vectors HNF4exp or pcDNA3.1 were transfected into HepG2 cells. After 48 h, the cells were fixed with 1 % formaldehyde and harvested. As shown in Figure 5 (d), a 228 bp fragment was amplified from the HNF4α-overexpressed cells, indicating that HNF4α could be interacting with the hHSS promoter in vivo.
To further demonstrate that HNF4α is specifically binding to the hHSS promoter at −209/−204, ChIP was performed in HepG2 cells transiently transfected with wild-type and mutant hHSS promoter constructs. ChIP was performed 48 h after transfection. As shown in Figure 5 To investigate further the inhibitory role of HNF4α on hHSS gene regulation, we used an siRNA approach to knockdown the endogenous expression of HNF4α in HepG2 cells and to determine the level of hHSS mRNA expression. The efficiency and specificity of HNF4α siRNA were examined by Western blot analysis. The HNF4α protein level was significantly decreased after 72 h incubation with siRNA (Figure 6b ), indicating that HNF4α was efficiently repressed. As expected, hHSS mRNA levels were correlatively increased by 80 % (Figure 6c) , which is consistent with the results above.
These results indicated that HNF4α directly interacts with the hHSS promoter region −209/−204 in vivo and strongly represses hHSS expression.
HNF4α1, but not HNF4α7, represses hHSS promoter activity
After confirmation of HNF4α affecting the promoter activity, we attempted to analyse whether two isoforms of HNF4α, HNF4α1 and HNF4α7, would be able to regulate expression of hHSS mRNA in HepG2 cells. To do this, the HNF4α1 and HNF4α7 expression vectors were transfected into the cells and hHSS mRNA expression was measured after 48 h. Figure 5(f) shows that the relative hHSS mRNA level was dramatically reduced to 40 % when HNF4α1 was overexpressed, whereas the overexpression of HNF4α7 had no effect on the hHSS expression (P > 0.05). The effects of HNF4α1 and HNF4α7 on hHSS promoter activity were then investigated by co-transfection experiments in HepG2 and HNF4α-deficient HEK-293T cells. Figure 5(g) illustrates that the co-transfection of HNF4α1 with the hHSS promoter-containing vector (P212-luc) dramatically inhibited the promoter activity to ∼50 % of control in both cell lines. However, co-transfection of the mutant HNF4α vector (MHNF4 P212-luc) with HNF4α1 and HNF4α7 was unable to alter the promoter activity (Figure 5h) . These results suggested that HNF4α1 exerted a repressive effect on hHSS expression whereas HNF4α7 had no effect on it.
Effects of DEX
As mentioned above, HNF4α plays an important role in HSS expression via interaction with its specific site on the proximal promoter. DEX has been reported to act as a regulator of HNF4α and is probably related to hepatocyte differentiation and maturation [17] . Many molecules involved in liver regeneration can be suppressed by DEX, such as uPAR (urokinase-type plasminogen activator receptor) and FGF (fibroblast grwoth factor) receptor 1 [18] . Hence, we used DEX to explore whether it stimulates HNF4α expression and, if so, could it be responsible for HNF4α-dependent hHSS transcription in HepG2 cells.
DEX inhibits the expression of hHSS mRNA
To determine whether DEX affects the expression of hHSS mRNA, HepG2 cells that constitutively expressed hHSS were To elucidate whether DEX can suppress the expression of hHSS at the transcriptional level, P212-luc, which contains the essential regulatory elements HNF4α (Figure 1) , was transiently transfected into HepG2 cells, and the cells were subsequently treated with DEX. As shown in Figure 7(b) , incubation of the cells with DEX (0.001, 0.01, 0.1 and 1.0 μM) suppressed the promoter activity by 20-50 % with concentration-dependent characteristics. The maximum reduction was found when the cells were treated with 0.1 μM DEX. If the cells were transiently transfected with MHNF4 P212-luc, bearing a mutation in the HNF4α site, before DEX treatment, the promoter activity appeared unchanged (Figure 7b, lower panel) . These results indicated that DEX can inhibit hHSS expression at the transcription level through the HNF4α site, and consequently, 0.1 μM DEX was used in the following experiments, since 0.1 μM DEX was usually employed to treat cells according to previous studies [19] .
To help clarify the role of the HNF4α site (−209/−204), we employed the decoy assay by designing two pairs of decoy ODNs (ODN212 and ODN MHNF4212, Table 1 ). This strategy was based upon the hypothetical competition between the decoy and target sequences for binding to the endogenous HNF4α site (Figure 8a) . TGTCCT, which served as a decoy oligo, was the consensus sequence of the HNF4α-binding site found in the hHSS promoter. The HNF4α decoy (ODN212 or ODNMHNF4 212) was transfected into HepG2 cells with the hHSS promoter reporter plasmid P212-luc, and subsequently the cells were treated with DEX. Figure 8 (b) shows that transfection of HepG2 cells with ODN212 prior to stimulation with DEX resulted in marked attenuation of DEX-induced luciferase activity down-regulation. In contrast, ODNs containing a mutated HNF4α site had no effect on DEX-mediated suppression. Taken together, these results implied that the HNF4α site (−209/−204) is functionally involved in mediating the DEXinduced repression on the hHSS transcription.
To further confirm the above results, we performed ChIP. Figure 9 (a) shows that, after the cells were treated with DEX for 48 h, the anti-HNF4α-antibody-immunoprecipitated DNA produced a positive band by PCR amplification, whereas the antibody failed to immunoprecipitate DNA if the cells were not stimulated by DEX. Therefore we are confident that DEX can suppress hHSS gene expression by inducing the direct binding of HNF4α to the hHSS promoter site.
We next investigated the mechanism that DEX utilizes to downregulate hHSS gene expression. It has been previously reported that hepatic HNF4α is transcriptionally activated by DEX [20] . (a) ChIP analyses of DNA-binding activity of HNF4 in vivo. HepG2 cells were treated with or without the indicated concentrations of DEX for 48 h, and then applied to a ChIP assay using anti-HNF4 antibodies, no antibody and normal rabbit serum (negative control) respectively. Samples extracted after the ChIP assay were subjected to PCR amplification using the same specific primers as those in Figure 5 . (b) Western blot analysis of cytosolic and nuclear HNF4 was performed as described in the Experimental section. A significant increase in cytosolic HNF4 was found in DEX-treated cells compared with untreated cells (left-hand side). The HNF4 protein level in the nucleus was not significantly affected by DEX treatment (right-hand side). (c) Effects of DEX on the DNA-binding activity of HNF4 in HepG2 cells. Nuclear extracts were prepared from HepG2 cells incubated with or without the indicated concentrations of DEX for 48 h. EMSA was performed using biotin-labelled P212192 as described in the Experimental section.
Therefore we tested the effects of DEX on the expression of endogenous HNF4α in HepG2 cells by Western blot analysis. As shown in Figure 9 (b), HNF4α both in cytosol and nuclear compartments was significantly increased when cells were treated with DEX. This result indicated that the ability of DEX to inhibit hHSS gene expression is due to the increase in HNF4α expression.
Because the HNF4α site was important in the transcriptional control of hHSS by DEX, we also suspected that DEX, apart from stimulating HNF4α expression, might also strengthen its binding to promoter DNA. To confirm this hypothesis, we performed an EMSA using nuclear extracts from HepG2 cells treated with DEX for 48 h. Figure 9(c) shows that the DNA-binding activity of HNF4α to the element located from −212 to −192 of the hHSS promoter was enhanced by DEX. The DNA-protein complex was specifically eliminated with a 200-fold molar excess of competitor. These results suggested that the increase in the amount of HNF4α-DNA complex induced by DEX is caused by augmentation of DNA binding.
DISCUSSION
Sp1 is the founding member of a growing family that binds to and acts through the GC box [21] . Sp1 sites have been shown to be key elements for the basal transcription of TATAless promoters, and are responsible for recruiting TATA-binding protein and fixing the transcription start site [22] . Because the hHSS promoter is TATA-less, we focused first on the Sp1 site (−152/−145) using promoter deletion and mutation experiments. Several experimental approaches were used to identify the role of Sp1 in the basal expression of the hHSS gene. Our results supported the hypothesis that Sp1 functions as an essential transcriptional activator of hHSS basal expression by binding to the Sp1 site (−152/−145). Most cell types constitutively express active Sp1, which is consistent with the expression profile of the hHSS gene existing in almost all tissues [9] .
In the present study, another transcription factor, HNF4α, which played an important role in the regulation of hHSS gene expression was also reported. An HNF4α-binding site (DR-1) was identified at −209 to −204 within the hHSS promoter, and HNF4α could bind to this region and suppress hHSS gene expression. In fact, a recent genome-wide analysis (ChIP-on-chip) showed that HNF4α is associated with the promoters of thousands of genes in human hepatocytes. These results included the hHSS gene, which has also been called GFER (growth factor erv1) [23] , although specific binding sites were not identified in the GFER promoter. It was indicated that HNF4α inhibited hHSS gene transcription in the present study. Recent studies have also shown that the CDC25A (cell division cycle 25 A) gene, involved in promoting cell-cycle progression, has been found, in expression profiling studies, to be down-regulated by HNF4α1 using HepG2 cells [24] .
Nevertheless, ChIP assays indicated that HNF4α is not required for the constitutive expression of the hHSS gene in HepG2 cells, because HNF4α was not associated with the HNF4α-binding site in vivo. These results could explain the high level of hHSS expression in the liver that existed simultaneously with abundant levels of HNF4α. Interestingly, over-expression of HNF4α induced the HNF4α interaction with its binding site in the hHSS promoter (Figure 5d ). This may suggest that this site binds well to other factors in vivo (that we did not identify in in vitro experiments), such as COUP-TF (chicken ovalbumin upstream promoter-transcription factor) [25] or c-myc [24] . These factors are present in HepG2 cells and positively regulated the hHSS promoter either by direct binding or due to competition with factors, such as HNF4α, for binding to this site. The expression level of another factor/HNF4α target gene would therefore depend on the relative concentrations of both transcription factors in a given cell type or during a certain condition. For instance, the age-dependent diminution of apoA1 (apolipoprotein A1) gene expression has been shown to occur at the transcriptional level, and to be associated with a decrease in the binding capacity and expression of HNF4 with a parallel increase in COUP-TF binding and concentration levels [26] . Previous studies have shown that HNF4α expression is lower than normal or completely lost in hepatocellular carcinoma cells [27] . Previous experiments show an increase in hHSS expression in human liver carcinoma [8] , which is consistent with the observed behaviour of the HNF4α gene in vivo. In addition, we found that HNF4α1 also repressed the hHSS transcription, whereas HNF4α7 did not affect it. Considering that the HNF4α1 isoform is expressed at high levels in adult liver and the HNF4α7 isoform is expressed at high levels in human liver carcinoma, these results could explain why hHSS was highly expressed in hepatocellular carcinoma cells, in contrast with a low-level expression in adult liver. In fact, a recent study showed that HNF4α1 repressed the expression of the constitutive androstane receptor gene [28] . The molecular mechanisms described above can also explain the increased expression of the hHSS gene in the liver carcinoma, which may be relevant to determining the progression of carcinogenesis.
There are only a few reports on the regulation of the hHSS gene, and the effects of corticosteroids (DEX), which play important roles in hepatic biology on gene expression, have not been explored. Finally, in the present study, we investigated the regulation of the hHSS gene by DEX in HepG2 cells. The results presented here demonstrate, for the first time, that DEX reduced the level of hHSS mRNA in HepG2 cells, and the suppression of hHSS promoter activity by DEX was HNF4α-dependent.
Because DEX suppressed hHSS expression at the transcriptional level (Figure 7a ), we sought to identify the cis-regulatory elements involved in this regulation. Functional analysis of the hHSS promoter revealed the existence of the HNF4α-binding site (−209/−204) that was crucial for suppression by DEX (Figure 7b) . Mutation of this site completely disrupted the ability of DEX to inhibit the hHSS promoter activity (Figure 7b) . Furthermore, in the decoy assay, the HNF4 decoy succeeded in eliminating repression of hHSS promoter activity by DEX (Figure 8b ). In addition, there is a more significant reduction in hHSS mRNA expression when 0.1 μM DEX was administered as compared with 1.0 μM DEX, and the reason may be related to saturability of the hormone receptor. These results suggest that (i) the DEXmediated inhibition of hHSS gene expression was specific via the HNF4α-binding site, and (ii) HNF4α and the HNF4α-binding site are necessary for DEX repression. The direct evidence was that HNF4α bound to the hHSS promoter in DEX-treated cells, but not in the untreated cells, as observed in ChIP assays (Figure 9a ). Taken together, the results clearly indicated that the effects of DEX were a secondary action and HNF4α-dependent.
The mechanism by which HNF4α mediates DEX-induced down-regulation of hHSS expression was then studied. Regulation of HNF4α expression by DEX could be one possible mechanism [17] . The other possible reason is that hormones often change patterns of gene expression in target cells by activating protein kinases that phosphorylate and modify the activity of different transcription factors. HNF4α can be acetylated, phosphorylated and bound to Smad 3 and 4 to enhance its activity [29] . So we preformed the gel-shift assay to observe the DNA-binding activity of HNF4α. The signal of a DNA-protein complex significantly increased when nuclear extracts from the DEXstimulated cells were used in EMSA (Figure 9c ). Therefore these results suggested that DEX induction of the expression of HNF4α, as well as the elevated DNA-binding activity of HNF4α, accounted for the majority of DEX-mediated down-regulation of hHSS gene expression. Taken together, Sp1 regulated hHSS basal expression via an Sp1-binding site (−152/−145) in the hHSS promoter, whereas HNF4α suppressed hHSS gene expression in some conditions, specifically overexpression of HNF4α and DEX stimulation in the present study. 
